Wells Fargo & Company Marker Therapeutics, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.24 - $4.58 $2 - $45	10 Added 0.37%	2,727 $0
Q3 2022 Nov 14, 2022	SELL	$0.3 - $3.73 $2 - $33	-9 Reduced 0.33%	2,717 $1,000
Q2 2022 Aug 12, 2022	BUY	$0.26 - $0.46 $9 - $16	35 Added 1.3%	2,726 $1,000
Q1 2022 May 16, 2022	BUY	$0.37 - $1.0 $0 - $1	1 Added 0.04%	2,691 $1,000
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.72 $950 - $1,720	-1,000 Reduced 27.1%	2,690 $2,000
Q3 2021 Nov 15, 2021	SELL	$1.68 - $2.88 $57 - $97	-34 Reduced 0.91%	3,690 $7,000
Q2 2021 Aug 16, 2021	SELL	$1.88 - $3.56 $13,259 - $25,108	-7,053 Reduced 65.44%	3,724 $10,000
Q1 2021 May 13, 2021	SELL	$1.47 - $3.29 $60,469 - $135,337	-41,136 Reduced 79.24%	10,777 $23,000
Q4 2020 Feb 09, 2021	SELL	$1.36 - $1.75 $47,279 - $60,837	-34,764 Reduced 40.11%	51,913 $75,000
Q3 2020 Nov 05, 2020	SELL	$1.5 - $2.2 $5,913 - $8,672	-3,942 Reduced 4.35%	86,677 $130,000
Q2 2020 Aug 13, 2020	BUY	$1.69 - $2.79 $105,143 - $173,579	62,215 Added 219.04%	90,619 $188,000
Q1 2020 May 14, 2020	BUY	$1.59 - $3.35 $45,162 - $95,153	28,404 New	28,404 $54,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $255M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.